BioSpace News Archive

Nephrologist and researcher Susan Hedayati, MD, MHSc, will be honored by the National Kidney Foundation with the prestigious Shaul G. Massry Distinguished Lecture at one of the nation’s most regarded gatherings of kidney professionals in 2023 for her discoveries in kidney disease.

The American Association of Medical Assistants® announced the installation of Deborah Novak, CMA, as the organization’s newly elected 2022-2023 president at the 66th AAMA Annual Conference.

At Vetter, a globally leading contract development and manufacturing organization (CDMO), numerous ideas for improving processes and further development of the overall company have been coming directly from colleagues in various departments

Eargo, Inc., a medical device company on a mission to improve the quality of life of people with hearing loss, is pleased to announce that Patient Square Capital has become the majority equity owner of the Company.

Voyager Therapeutics, Inc. has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD).

Taysha Gene Therapies, Inc. announced that it will participate in the JMP Securities Hematology and Oncology Summit, which is taking place virtually from Tuesday, December 6, 2022, through Wednesday, December 7, 2022.

Theralink Technologies, Inc. announced that it has entered into definitive agreements with certain institutional and accredited investors for the sale of senior secured convertible debentures and warrants to purchase shares of the Company’s common stock, resulting in total gross proceeds of approximately $3.1 million before deducting the placement agent’s fees and other offering expenses.

Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced that Company leadership will participate in three upcoming investor conferences.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.